UL Solutions Free cash flow increased by 74.4% to $150.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 45.6%, from $103.00M to $150.00M. Over 3 years (FY 2022 to FY 2025), Free cash flow shows an upward trend with a 24.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.00M | $52.00M | $52.00M | $52.00M | $98.00M | $9.00M | $78.00M | $67.00M | $84.00M | $47.00M | $84.00M | $72.00M | $103.00M | $105.00M | $109.00M | $86.00M | $150.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +88.5% | -90.8% | +766.7% | -14.1% | +25.4% | -44.0% | +78.7% | -14.3% | +43.1% | +1.9% | +3.8% | -21.1% | +74.4% |
| YoY Change | — | — | — | — | +88.5% | -82.7% | +50.0% | +28.8% | -14.3% | +422.2% | +7.7% | +7.5% | +22.6% | +123.4% | +29.8% | +19.4% | +45.6% |